Mr Alistair Taylor - Non-Executive Chairman

Mr Taylor is formerly Executive Chairman of UK listed Lombard Medical Technologies plc and has 50 years’ experience in the healthcare industry; twelve years in pharmaceuticals and over 38 years in medical devices. He was Chief Executive Officer of Biocompatibles International plc from 1994 to 1998 and during this period the company progressed from a technology-based start-up company, through flotation to a FTSE 250 company. Prior to this, Mr Taylor was Chief Executive Officer of Schneider Inc, a Swiss interventional cardiology/radiology device company and during this time the company’s turnover grew to $100 million. Schneider was subsequently sold by Pfizer Inc., its parent, for over $2 billion. Mr Taylor’s early career included the position of Financial Controller, Pfizer Hospital Products Inc. New York. He is also Executive Chairman of ORProductivity plc and Arterius Limited, as well as being Non-executive Chairman of Intelligent Orthopaedics Limited, Anaxsys Limited and Nightingale-EOS Limited. He is a chartered accountant.

Mr Tim Sharpington - Chief Executive

Mr Sharpington has more than 20 years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. He has broad experience across drug development, in-licensing, mergers and acquisitions as well as fundraisings. After a period of time at Pfizer, Mr Sharpington led product development at US-based Sequus Inc. in the late 1990’s. In 2002, Mr Sharpington was appointed as Development Director at Arakis Ltd, a UK-based VC-backed biotechnology company sold to Sosei in 2005 for £107 million. After leaving Arakis Mr Sharpington founded and became Chief Executive Officer of Serentis Limited in 2006. He joined Phytopharm as Chief Executive Officer in 2010.

Mr Roger Hickling - Research and Development Director

Mr Hickling has a BSc in Chemistry from Kings College, University of London and over 30 years’ experience in pharmaceutical research and development. This includes management of development portfolios and projects from preclinical through to Phase IV covering a range of disease areas. In addition, Mr Hickling has extensive experience in international regulatory affairs, including clinical trials and marketing applications. Between 1976 and 1998 Mr Hickling worked at SmithKline Beecham where he oversaw both in-house and partnered early stage neuroscience development projects. Mr Hickling held a variety of positions at several pharmaceutical companies between 1998 and 2009 including Alizyme Therapeutics plc. He was appointed to the Board of Alizyme Therapeutics as Research and Development Director in 2006 with responsibility for research and development strategy development, all research and development operations and staff.

Dr Peter Blower - Non-Executive Director

Dr Blower has over 40 years’ experience in medicinal research and development with a strong background in the field of neuroscience. He joined Beecham Research Laboratories in 1969 and rose to the position of Director of New Neuroscience products at SmithKline Beecham in 1996 before leaving in 2000 to form his own consultancy company. He has been elected to Fellowship of the Royal Society of Medicine and the Institute of Biology and has authored over 70 scientific publications. He has a M.I.Biol from the Institute of Biology (1972), a PhD in Pharmacology from the University of Aston (1977) and a DSc from the University of East London (1997).

Dr Ian Tulloch - Non-Executive Director

Dr Tulloch has over 30 years' experience in the pharmaceutical industry, encompassing a broad range of senior roles in both research and development and commercial functions. He has a strong background in neuroscience, including both neurological and psychiatric disorders, and has been closely involved in the commercialisation of innovative products for the treatment of Parkinson's disease, depression, epilepsy, multiple sclerosis and pain. From 2002 to 2010 he was Global Marketing Director in the Neuroscience & Ophthalmics Business Franchise at Novartis AG, based in Basel, Switzerland, where he supported both in-line products and Phase II/III development candidates and also worked closely with Business Development & Licensing on in-licensing opportunities. Prior to this he held global medical marketing positions at GlaxoSmithKline/SmithKline Beecham, from 1990-2002, and was Drug Discovery Program Director at Reckitt Benckiser from 1978 to 1990. Dr Tulloch has a BSc (Hons) in Pharmacology and a PhD in Neuropharmacology, both from the University of Edinburgh. He has authored over 100 scientific publications in the neuroscience field.